PEDIATRICS Vol. 105 No. 4 April 2000, pp. 863-864
COMMENTARY:
What the Multimodal Treatment Study of
Children With Attention-Deficit/Hyperactivity Disorder Did and Did Not
Say About the Use of Methylphenidate for Attention Deficits
| The first 20% of the full text of this article appears below. |
The December 1999 issue of the Archives of General Psychiatry contained 2 articles1,2 and a commentary3 about the Multimodal Treatment Study of Children with attention-deficit/hyperactivity disorder (ADHD; MTA). At the time of publication the findings were reported widely in the general press with varying degrees of accuracy. A common misperception has been created that it concluded that methylphenidate (Ritalin) is the sole answer for children's problems with inattentiveness and activity and that behavioral management is not particularly beneficial. This commentary reviews what the report actually did and did not say. Misunderstandings by practitioners, teachers, and insurance companies could have unfortunate consequences.
WHAT DID THE REPORT SAY?
- In describing this 14-month investigation of 579 elementary school children 7 to 9 years of age, the National Institute
of Mental Health press release announced: "The MTA study has
demonstrated, on average, that carefully monitored medication
management with monthly follow-up, with input from teachers, is more
effective than intensive behavioral treatment for ADHD. The combination of medication management and intensive behavioral treatments was also
significantly superior to psychosocial treatments
. . . [Full Text of this Article]
This article has been cited by other articles:
![]() |
H. M. Schachter, B. Pham, J. King, S. Langford, and D. Moher How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis Can. Med. Assoc. J., November 1, 2001; 165(11): 1475 - 1488. [Abstract] [Full Text] [PDF] |
||||





